| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 108.02 | 1590.5% | 405.7% |
| Total Income | 108.02 | 1590.5% | 405.7% |
| Expenditure | 78.76 | 12.3% | 7.0% |
| PBT | — | ||
| Net Profit | 22.71 | 125.2% | 132.0% |
| OPM | 27.09% | ||
| NPM | 21.02% | ||
| EPS | 0.43 | 125.0% | 131.2% |
REGENXBIO Reports Q2 2026 Financial Results and Operational Highlights
06 Aug 2026 · 6 Aug, 4:43 pm
Summary
REGENXBIO reported strong financial results for the second quarter of 2026, with revenues reaching $108.0 million, significantly up from $21.4 million in Q2 2025, largely due to a $100 million milestone payment. The company achieved a net income of $22.7 million ($0.43 per share) compared to a net loss in the prior year. With pro forma cash exceeding $310 million as of June 30, 2026, REGENXBIO has extended its cash runway into Q4 2027. The company highlighted significant clinical progress, including the RGX-202 BLA submission on track for Q3 2026 and upcoming pivotal data for surabgene lomparvovec in wet AMD in Q4 2026.
Key Highlights
- 1
REGENXBIO reported revenues of $108.0 million for the three months ended June 30, 2026, a significant increase from $21.4 million in the same period of 2025, primarily driven by a $100 million development milestone payment.
- 2
The company achieved net income of $22.7 million, or $0.43 per share, for the second quarter of 2026, a substantial improvement from a net loss of $70.9 million in the prior year's quarter.
- 3
Pro forma cash, cash equivalents, and marketable securities as of June 30, 2026, were approximately $313 million, bolstered by recent capital raises and extending the company's expected cash runway into Q4 2027.
- 4
The RGX-202 BLA submission for Duchenne muscular dystrophy is on track for Q3 2026 initiation, with potential accelerated approval in the second half of 2027.
- 5
Topline data from the pivotal wet AMD studies, ATMOSPHERE® and ASCENT®, for surabgene lomparvovec are expected in Q4 2026.
- 6
REGENXBIO is on track to resubmit the BLA for RGX-121 for Hunter syndrome in Q3 2026 following a productive FDA Type A meeting.
Management Comments
Curran Simpson
Our second quarter was defined by strong clinical execution across our pipeline: the Phase III AFFINITY DUCHENNE® trial met its primary endpoint, we dosed the first participant in the NAAVIGATE study in diabetic retinopathy, and the FDA reaffirmed the path forward for RGX-121. With this progress and our strong cash runway, we are well positioned to deliver against multiple near-term, high-value catalysts, including the initiation of the RGX-202 BLA this quarter and wet AMD pivotal data in the coming months, as we advance potentially transformative gene therapies to patients.
Informational and educational content only. Not investment advice.